BioLM provides a high-throughput, low-cost infrastructure for protein and DNA language modeling, enabling biotech and life science companies to efficiently generate and optimize enzyme and antibody candidates. By leveraging advanced computational methods, BioLM accelerates the lead generation process, allowing clients to screen millions of variants in silico and validate them through wet lab testing.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech and life science companies face challenges in efficiently generating and optimizing enzyme and antibody candidates due to the high costs and time requirements of traditional methods. Screening millions of variants to identify leads and improve properties like thermostability and solubility is a computationally intensive and resource-heavy process.
Solution
BioLM provides a high-throughput infrastructure for protein and DNA language modeling, enabling efficient in-silico screening and optimization of enzyme and antibody candidates. By leveraging advanced computational methods and a model-agnostic approach, BioLM accelerates the lead generation process, allowing clients to screen millions of variants against numerous properties. The platform supports custom AI workflow development, including fine-tuning models, and offers both in-silico screening and wet lab validation through partners, closing the loop with AI-driven feedback.
Target Audience
The primary customers are biotech and life science companies seeking to accelerate lead generation and optimize enzyme and antibody properties through advanced computational methods.
Features
- Custom AI workflow development and model fine-tuning for specific tasks
- In-silico screening of millions of variants against multiple properties
- Model-agnostic approach adaptable to various experimental needs
- On-site GPU fleet for high-performance computing
- Integration of AI-driven insights into wet-lab projects
- Capabilities for enhancing enzyme thermostability, solubility, and expression